You will be redirected to the website of our parent company, Schönherr Rechtsanwälte GmbH: www.schoenherr.eu
Our Healthcare & Life Sciences team provides fully integrated legal advice across one of the most highly regulated and rapidly evolving industries. We combine deep, industry-specific regulatory expertise with comprehensive transactional, financing, dispute resolution, IP and compliance capabilities.
With offices across Central Eastern Europe, we advise clients on both complex domestic and multi-jurisdictional matters, seamlessly coordinating cross-border projects across the region.
We advise all key stakeholders active in these industries, including manufacturers, distributors and operators, hospitals, physicians, insurers and other healthcare and care institutions, as well as enterprises ranging from innovative start ups to established multinational corporations and strategic and financial investors.
Our core strengths lie in life sciences regulatory advice and transactional work, in particular M&A, VC/PE and spin-off transactions, capital markets transactions (including IPOs), and financing. As a full-service law firm, we support clients throughout the entire business and product life cycle – from early-stage innovation and investment to market expansion and mature international operations.
Our Healthcare & Life Sciences practice is structured around the needs of the industry. We bring together regulatory, transactional, corporate, IP and dispute resolution expertise to deliver practical, strategic and commercially driven advice in regulated environments.
We provide regulatory advice across the full spectrum of healthcare and life sciences products, including pharmaceuticals, medical devices, biotechnology, digital health, food and feed, seeds, chemicals, cosmetics and select consumer goods.
We provide comprehensive transactional and corporate advice for clients across the healthcare and life sciences value chain – from innovative start-ups and emerging growth companies to established multinational corporations – including regulated product manufacturers, healthcare providers, insurers, management teams and strategic and financial investors, as well as issuers and underwriters in capital markets transactions.
In addition, we provide full transactional support, from due diligence and deal structuring to closing and post-closing integration.
We provide advisory services for hospitals, outpatient clinics, physician centres, nursing and care facilities, and other healthcare providers, covering regulatory, corporate, transactional and contentious matters across the full spectrum of healthcare delivery.
In addition, we provide representation before national and European authorities and courts, including medical malpractice and professional liability claims.
We advice on the drafting, negotiation and implementation of sector-specific agreements across the healthcare and life sciences value chain, including complex cross-border contractual frameworks and long-term strategic partnerships.
In addition to our core regulatory and transactional practice, our clients benefit from seamless access to Schoenherr's dedicated specialists across a broad range of complementary practice areas essential to the healthcare and life sciences industries. These experts collaborate closely with our Healthcare & Life Sciences team to deliver comprehensive and fully integrated legal advice.
EU pathways to health innovation: the Biotech Act I and medical device reform
On 2 July 2025, the European Commission published its Strategy for European Life Sciences (see here), setting out the objective of positioning the EU as the world's most attractive place for life sciences by 2030. The strategy announces a series of flagship actions to foster a dynamic and competitive life sciences ecosystem.
The EU Medicinal Products Directive in the Balkans: are candidate countries aligned with its key provisions?
The European Commission has recognised the regulatory disparities that exist between EU Member States and the candidate Balkan countries. To address these differences, it has identified the need to assess national legal frameworks and provide recommendations to Balkan countries for aligning them with EU standards.
Austria/Belgium: Schoenherr advises FRI-Invest GmbH and its shareholders on Fluidda's acquisition by Banook
Schoenherr advised FRI-Invest GmbH and its shareholders on the transaction structure and Austrian law aspects of Fluidda's acquisition by Banook. Previously, Schoenherr had also advised FRI-Invest GmbH on its initial investment in Fluidda.
18 December 2025
austria bulgaria czech republic romania
S.Rosenthaler A.Natterer N.Kerschbaumer D.Birnbauer S.Sayahpour E.Todorova A.Minioti H.Hadzhiiliev M.Demirev K.Gabryjańczyk O.Grecu I.Sava
to the point: Healthcare & Life Sciences Q4/2025
Welcome to the second edition of to the point: Healthcare & Life Sciences – a new format designed to keep you informed about legal and regulatory developments shaping the sector across Europe.
The Legal 500 Country Comparative Guide 2025: Pharmaceutical Advertising in Bulgaria
Romania: Schoenherr advises Calla Oradea shareholders on sale of majority stake in clinic to Integral Capital Group
Schoenherr advised the founders of Calla Oradea, an infertility diagnosis and treatment centre, on the sale of a majority stake in the clinic to Integral Capital Group.
find all healthcare & life sciences news here